131I-mIBG therapy in relapsed/refractory neuroblastoma: A weapon from the future past

IF 5.5 2区医学 Q1 HEMATOLOGY

Critical reviews in oncology/hematology Pub Date : 2024-12-26 DOI:10.1016/j.critrevonc.2024.104606

Francesco Fabozzi , Maria Felicia Villani , Francesca Del Bufalo , Claudio Altini , Vittorio Cannatà , Ciucci Davide , Milena Pizzoferro , Margherita Drago , Federica D’Antonio , Elizabeth Katherine Anna Triumbari , Angela Di Giannatale , Sabina Vennarini , Angela Mastronuzzi , Maria Antonietta De Ioris , Maria Carmen Garganese

{"title":"131I-mIBG therapy in relapsed/refractory neuroblastoma: A weapon from the future past","authors":"Francesco Fabozzi , Maria Felicia Villani , Francesca Del Bufalo , Claudio Altini , Vittorio Cannatà , Ciucci Davide , Milena Pizzoferro , Margherita Drago , Federica D’Antonio , Elizabeth Katherine Anna Triumbari , Angela Di Giannatale , Sabina Vennarini , Angela Mastronuzzi , Maria Antonietta De Ioris , Maria Carmen Garganese","doi":"10.1016/j.critrevonc.2024.104606","DOIUrl":null,"url":null,"abstract":"<div><div>Neuroblastoma (NB) is the most common extracranial solid tumor in children, with variable outcomes ranging from spontaneous remission to high-risk cases often leading to relapse or refractory disease. Approximately 50 % of patients with NB have high-risk features, often experiencing relapse or refractory disease despite intensive treatments and the prognosis remains poor, with long-term event-free survival (EFS) rates below 10 %,Radioactive iodine-labeled meta-iodobenzylguanidine (¹³¹I-mIBG) therapy, leveraging NB cells' radiosensitivity and expression of the norepinephrine transporter (NET), has shown promise in treating relapsed or refractory NB. Since 1985, ¹³¹I-mIBG has been studied to determine the maximum tolerated dose and side effects, with recent trials exploring its use in front-line treatment. Our systematic review, based on MEDLINE, EMBASE, and Cochrane CENTRAL databases up to December 2023, evaluates the effectiveness and toxicity of ¹³¹I-mIBG therapy in relapsed/refractory NB. It also discusses its potential role in conjunction with emerging therapies like CAR-T cells, haploidentical stem cell transplantation, and dinutuximab beta.</div></div>","PeriodicalId":11358,"journal":{"name":"Critical reviews in oncology/hematology","volume":"207 ","pages":"Article 104606"},"PeriodicalIF":5.5000,"publicationDate":"2024-12-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Critical reviews in oncology/hematology","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1040842824003494","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"HEMATOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Neuroblastoma (NB) is the most common extracranial solid tumor in children, with variable outcomes ranging from spontaneous remission to high-risk cases often leading to relapse or refractory disease. Approximately 50 % of patients with NB have high-risk features, often experiencing relapse or refractory disease despite intensive treatments and the prognosis remains poor, with long-term event-free survival (EFS) rates below 10 %,Radioactive iodine-labeled meta-iodobenzylguanidine (¹³¹I-mIBG) therapy, leveraging NB cells' radiosensitivity and expression of the norepinephrine transporter (NET), has shown promise in treating relapsed or refractory NB. Since 1985, ¹³¹I-mIBG has been studied to determine the maximum tolerated dose and side effects, with recent trials exploring its use in front-line treatment. Our systematic review, based on MEDLINE, EMBASE, and Cochrane CENTRAL databases up to December 2023, evaluates the effectiveness and toxicity of ¹³¹I-mIBG therapy in relapsed/refractory NB. It also discusses its potential role in conjunction with emerging therapies like CAR-T cells, haploidentical stem cell transplantation, and dinutuximab beta.

查看原文本刊更多论文

i - mibg治疗复发/难治性神经母细胞瘤：来自未来的武器。

神经母细胞瘤（Neuroblastoma， NB）是儿童中最常见的颅外实体瘤，其结局多种多样，从自发缓解到高风险病例，往往导致复发或难治性疾病。大约50%的NB患者具有高风险特征，尽管进行了强化治疗，但仍经常复发或难治性疾病，预后仍然很差，长期无事件生存率（EFS）低于10%，放射性碘标记的间碘苄基胍（¹³¹I-mIBG）治疗，利用NB细胞的放射敏感性和去甲肾上腺素转运体（NET）的表达，在治疗复发或难治性NB方面显示出希望。自1985年以来，人们对I-mIBG进行了研究，以确定最大耐受剂量和副作用，最近的试验探索其在一线治疗中的应用。我们的系统综述基于MEDLINE、EMBASE和Cochrane CENTRAL数据库，截止到2023年12月，评估了1³1 I-mIBG治疗复发/难治性NB的有效性和毒性。它还讨论了它与新兴疗法如CAR-T细胞、单倍体干细胞移植和迪努妥昔单抗结合的潜在作用。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Critical reviews in oncology/hematology 医学-血液学

CiteScore

11.00

自引率

3.20%

发文量

213

审稿时长

55 days

期刊介绍： Critical Reviews in Oncology/Hematology publishes scholarly, critical reviews in all fields of oncology and hematology written by experts from around the world. Critical Reviews in Oncology/Hematology is the Official Journal of the European School of Oncology (ESO) and the International Society of Liquid Biopsy.